Treprostinil Therapy for Interstitial Lung Disease FVC Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new pharmaceutical treatments for interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF), as the current FDA-approved drugs have limited efficacy and the average survival rate for ILD patients is between 3 to 5 years.
Innovation Solution
Administering treprostinil, a prodrug, salt, or ester thereof, to subjects with ILD or pulmonary hypertension associated with ILD, to improve pulmonary function and increase forced vital capacity (FVC) through various administration methods, including inhalation, subcutaneous, and intravenous routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved drugs (nintedanib and pirfenidone) are used for treating IPF, then treatment is available, but efficacy is limited and survival rate remains low (3-5 years)
Solution Approach 1:
The patent changes the pharmacological parameter by introducing a different drug class (prostacyclin analogs) with novel mechanisms of action compared to existing antifibrotics. This parameter change in therapeutic approach aims to overcome the limited efficacy and poor survival outcomes associated with current FDA-approved treatments for IPF
2Reliability
If new pharmaceutical treatments are developed for ILD, then treatment efficacy may improve, but development time and resources increase
Solution Approach 1:
The patent applies preliminary action by conducting extensive preclinical studies including animal models of pulmonary fibrosis, in vitro studies with human lung fibroblasts, and pharmacokinetic evaluations before advancing to clinical trials. This thorough preliminary characterization of the prostacyclin analog's safety, efficacy, and pharmacological properties accelerates the overall development timeline by reducing uncertainties in later stages
Data Source
AI summary
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.